Evaluate the Therapeutic Response by Using in Vitro Circulating Tumor Cell Expansion System( I )

Translational medicine presents explosive growth in last two decades. Although, targeted and immune therapies are well development, therapies and prognosis of pancreatic cancer are still limited. About 85% patients is pancreatic ductal adenocarcinoma (PDAC) in pancreatic carcinoma. Over 95% malignant pancreatic carcinoma is from exocrine glands and only 5% is from endocrine glands. The mortality is high in patients with pancreatic carcinoma compared with other cancer. PDAC therapies is including radiation, immunotherapy, targeted therapy, and surgery but these therapies still can not increase the 5 years survival rates for the past thirty years. The reason is that it is hard to track and eliminate tumor cells with useful therapeutic strategy. To overcome these problems, our group will use circulating tumor cell (CTC) to develop medicine sensitivity platform. PDAC cells and gene mutation can be tracked and analyzed effectively by this platform. Furthermore, suitable dose and drugs can be selected to promote medical benefit and quality. Not only help doctor to understand the sensitivity of therapy in PDAC patients but also support great applied potential of CTC precision medicine in this project.